WO2000006183A1 - Nouvelle sous-unite beta du canal a potassium, c7f2-a - Google Patents

Nouvelle sous-unite beta du canal a potassium, c7f2-a Download PDF

Info

Publication number
WO2000006183A1
WO2000006183A1 PCT/US1999/016949 US9916949W WO0006183A1 WO 2000006183 A1 WO2000006183 A1 WO 2000006183A1 US 9916949 W US9916949 W US 9916949W WO 0006183 A1 WO0006183 A1 WO 0006183A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
subunit
seq
protein
Prior art date
Application number
PCT/US1999/016949
Other languages
English (en)
Inventor
Rory Curtis
Maria Alexandra Glucksmann
Original Assignee
Millennium Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals, Inc. filed Critical Millennium Pharmaceuticals, Inc.
Priority to MXPA01000952A priority Critical patent/MXPA01000952A/es
Priority to JP2000562037A priority patent/JP2002524030A/ja
Priority to EP99937511A priority patent/EP1100521A4/fr
Priority to AU52327/99A priority patent/AU5232799A/en
Priority to CA002335643A priority patent/CA2335643A1/fr
Publication of WO2000006183A1 publication Critical patent/WO2000006183A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)

Abstract

La présente invention concerne une sous-unité bêta du canal à potassium nouvellement identifiée, et des polynucléotides codant ladite sous-unité. L'invention concerne également des procédés qui mettent en oeuvre les polypeptides et polynucléotides de ladite sous-unité et conviennent pour le diagnostic ou le traitement de troubles liés au canal. L'invention concerne en outre des procédés de criblage de médicaments qui mettent en oeuvre les polypeptides et polynucléotides de l'invention pour identifier des agonistes et des antagonistes, et conviennent pour des applications diagnostiques ou thérapeutiques. Elle concerne des agonistes et des antagonistes basés sur les polypeptides et polynucléotides de l'invention. L'invention concerne enfin des procédés de production des polypeptides et polynucléotides de ladite sous-unité.
PCT/US1999/016949 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a WO2000006183A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
MXPA01000952A MXPA01000952A (es) 1998-07-27 1999-07-27 Nueva -subunidad del canal de potasio, c7f2-a.
JP2000562037A JP2002524030A (ja) 1998-07-27 1999-07-27 Ｃ７Ｆ２−新規カリウムチャネルβサブユニット
EP99937511A EP1100521A4 (fr) 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a
AU52327/99A AU5232799A (en) 1998-07-27 1999-07-27 C7f2-a novel potassium channel beta-subunit
CA002335643A CA2335643A1 (fr) 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12302098A 1998-07-27 1998-07-27
US09/123,020 1998-07-27

Publications (1)

Publication Number Publication Date
WO2000006183A1 true WO2000006183A1 (fr) 2000-02-10

Family

ID=22406262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/016949 WO2000006183A1 (fr) 1998-07-27 1999-07-27 Nouvelle sous-unite beta du canal a potassium, c7f2-a

Country Status (6)

Country Link
EP (1) EP1100521A4 (fr)
JP (1) JP2002524030A (fr)
AU (1) AU5232799A (fr)
CA (1) CA2335643A1 (fr)
MX (1) MXPA01000952A (fr)
WO (1) WO2000006183A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000821A2 (fr) * 2000-06-21 2002-01-03 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine plp 39, et polynucleotide codant ce polypeptide
AU768352B2 (en) * 1999-02-23 2003-12-11 Icagen, Inc. BK beta subunits of SLO family potassium channels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031543A1 (fr) * 1994-05-13 1995-11-23 Merck & Co., Inc. Adn codant la sous-unite beta d'un canal potassique 'maxi k' de mammifere
US5508164A (en) * 1990-10-29 1996-04-16 Dekalb Genetics Corporation Isolation of biological materials using magnetic particles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936271A1 (fr) * 1998-02-17 1999-08-18 Synthelabo Le gène et la protéine de la sous-unité beta du canal de potassium activé par le calcium

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5508164A (en) * 1990-10-29 1996-04-16 Dekalb Genetics Corporation Isolation of biological materials using magnetic particles
WO1995031543A1 (fr) * 1994-05-13 1995-11-23 Merck & Co., Inc. Adn codant la sous-unite beta d'un canal potassique 'maxi k' de mammifere

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1100521A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU768352B2 (en) * 1999-02-23 2003-12-11 Icagen, Inc. BK beta subunits of SLO family potassium channels
WO2002000821A2 (fr) * 2000-06-21 2002-01-03 Biowindow Gene Development Inc. Shanghai Nouveau polypeptide, proteine humaine plp 39, et polynucleotide codant ce polypeptide
WO2002000821A3 (fr) * 2000-06-21 2002-05-10 Biowindow Gene Dev Inc Nouveau polypeptide, proteine humaine plp 39, et polynucleotide codant ce polypeptide

Also Published As

Publication number Publication date
EP1100521A1 (fr) 2001-05-23
EP1100521A4 (fr) 2002-10-09
JP2002524030A (ja) 2002-08-06
AU5232799A (en) 2000-02-21
CA2335643A1 (fr) 2000-02-10
MXPA01000952A (es) 2002-08-20

Similar Documents

Publication Publication Date Title
US7057028B2 (en) 14273 Receptor, a novel G-protein coupled receptor
WO2002095049A2 (fr) Proteines isolees secretees par l'humain, molecules d'acides nucleiques codant pour ces proteines secretees par l'humain et leur utilisation
AU4544999A (en) G-protein coupled receptor, named 2871 receptor
CA2451217A1 (fr) Proteines humaines secretees et isolees, molecules d'acide nucleique codant les proteines humaines secretees et utilisation de ces dernieres
WO2000006183A1 (fr) Nouvelle sous-unite beta du canal a potassium, c7f2-a
EP1414422A2 (fr) Proteines humaines isolees secretees, molecules d'acides nucleiques codant pour lesdites proteines et utilisations de ces proteines
US20060002919A1 (en) 15625 receptor, a novel G-protein coupled receptor
US20050130218A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
US20030022299A1 (en) Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof
EP1278776A2 (fr) Proteines de transport humaines isolees, molecules d'acides nucleiques codant pour les proteines de transport humaines et utilisations associees
EP1414863A2 (fr) Proteines secretees humaines isolees, molecules d'acide nucleique codantes pour ces proteines secretees humaines et utilisations de celles-ci
WO2000043513A1 (fr) Recepteur 17723 couple a la proteine g
US20030013155A1 (en) 14400 receptor, a novel G-protein coupled receptor
US20060051850A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
EP1392343A2 (fr) Proteines secretees humaines isolees, molecules d'acide nucleique codant pour ces proteines secretees humaines et utilisations de ces dernieres
CA2409077A1 (fr) Proteines de transport humaines isolees, molecules d'acide nucleique codant pour les proteines de transport humaines, et utilisations
CA2447931A1 (fr) Proteines humaines secretees isolees, molecules d'acides nucleiques codant pour les proteines humaines secretees et leurs utilisations
WO2003006481A2 (fr) Proteines secretees humaines isolees, molecules d'acides nucleiques codant pour ces proteines, et utilisation de celles-ci
EP1404358A2 (fr) Proteines humaines secretees isolees, molecules d'acides nucleiques codant pour les proteines humaines secretees isolees et leur utilisation
EP1414983A1 (fr) Proteines isolees secretees par le corps humain, molecules d'acide nucleique codant des proteines secretees par le corps humain, et leurs utilisations
MXPA00012953A (en) 14273 receptor, a g-protein coupled receptor
EP1392716A1 (fr) Proteines humaines secretees isolees, molecules d'acide nucleique codant ces proteines, et utilisation de ces proteines
WO2002064628A2 (fr) Proteines humaines de transport isolees, molecules d'acides nucleiques codant pour ces proteines et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2335643

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999937511

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000952

Country of ref document: MX

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 562037

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 52327/99

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1999937511

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999937511

Country of ref document: EP